In VivoIN VITRO DIAGNOSTICS Financings Accelerate Diagnostics Inc. Infectious disease-focused Accelerate Diagnostics Inc. netted $74.6mm through the upsized follow-on offering of 2.75mm common shares pri
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in
Pink SheetSEOUL - South Korea will raise the prices of “global innovative novel drugs” and biomedicines, and shorten the period before national health insurance listing, to provide incentives for R&D spending a
ScripD-Pharm's local licensee Yungjin Pharmaceutical has received approval from South Korea's FDA to begin a Phase III trial in the country with D-Pharm's neuroprotective and lead product candidate DP-b99.